News
ORKA
109.50
+4.72%
4.94
Oruka Therapeutics Faces Patent Expiry Risk That Could Accelerate Generic Competition and Pressure Future Revenues
TipRanks · 5h ago
Oruka Therapeutics reports Q3 EPS (63c), consensus (62c)
TipRanks · 17h ago
Oruka's December Readout Will Test Whether Psoriasis Data Justify the Burn Rate
Barchart · 19h ago
Oruka Expects ORKA-001 52-Week Data In December; Phase 3 Start Planned For 2027
NASDAQ · 20h ago
Oruka Therapeutics (ORKA) Receives a Buy from UBS
TipRanks · 20h ago
Piper Sandler Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)
TipRanks · 22h ago
Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
TipRanks · 22h ago
BTIG Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 23h ago
Oruka Therapeutics Price Target Maintained With a $151.00/Share by BTIG
Dow Jones · 1d ago
Oruka Therapeutics GAAP EPS of -$0.63 in-line
Seeking Alpha · 1d ago
Oruka Therapeutics Q3 EPS $(0.63) Misses $(0.60) Estimate
Benzinga · 1d ago
Weekly Report: what happened at ORKA last week (1102-1106)?
Weekly Report · 2d ago
Weekly Report: what happened at ORKA last week (1026-1030)?
Weekly Report · 11/02 09:01
Analysts Offer Insights on Healthcare Companies: Avantor (AVTR), Oruka Therapeutics (ORKA) and Universal Health (UHS)
TipRanks · 10/28 08:01
Oruka Therapeutics Price Target Maintained With a $200.00/Share by Guggenheim
Dow Jones · 10/27 13:47
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Benzinga · 10/27 13:37
Wedbush Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 10/27 13:36
Oruka Therapeutics Price Target Maintained With a $165.00/Share by Wedbush
Dow Jones · 10/27 13:29
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
Benzinga · 10/27 10:39
Barclays Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 10/27 08:55
More
Webull provides a variety of real-time ORKA stock news. You can receive the latest news about Oruka Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).